InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2026)

InMed Pharmaceuticals' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2791751.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 35.06% year-over-year to 2791751.0 in Q1 2026; TTM through Mar 2026 was 7853314.0, a 4.81% increase from a year earlier, with the FY2025 full-year figure at 8162133.0, down 6.34% from the prior year.
• Income from Continuing Operations fell to 2791751.0 in Q1 2026 per INM's latest filing, from 2028223.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 336591.0 in Q2 2023 and bottomed at 7870023.0 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 2028223.0 (2025), against an average of 2419337.35.
• Across the five-year window, Income from Continuing Operations soared 95.72% in 2023 and tumbled 473.57% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 2098087.0 in 2022, then climbed by 29.55% to 1478185.0 in 2023, then sank by 74.2% to 2575024.0 in 2024, then climbed by 21.23% to 2028223.0 in 2025, then tumbled by 37.65% to 2791751.0 in 2026.
• Per Business Quant, the three latest INM Income from Continuing Operations figures stand at 2791751.0 (Q1 2026), 2028223.0 (Q4 2025), and 1726899.0 (Q3 2025).